Archive for the News Category

Ceapro Inc. Announces the Grand Opening of New Bio-processing Extraction Facility

EDMONTON, ALBERTA – September 28, 2016 – Ceapro Inc. (TSX-V: CZO) (“Ceapro” or the “Company”), a growth-stage biotechnology company focused on the development and commercialization of active ingredients for healthcare and cosmetic industries, announced today the grand opening of its new 30,000-square-foot bioprocessing extraction/manufacturing facility in Edmonton,

Read more

Ceapro Inc. Awarded 2016 BioAlberta Achievement Award for Company of the Year

EDMONTON, ALBERTA – September 27, 2016 – Ceapro Inc.  (TSX-V: CZO) (“Ceapro” or the “Company”), a growth-stage biotechnology company focused on the development and commercialization of active ingredients for healthcare and cosmetic industries, announced today that the Company has been awarded the 2016 BioAlberta Achievement Award for

Read more

Ceapro Inc. Awarded Research Grant from German-Canadian Centre for Innovation and Research – Ceapro Enters into a multi-partners’ project through Alberta-Germany Collaboration Fund for Product Development and Commercialization of PGX Technology

EDMONTON, ALBERTA – September 21, 2016 – Ceapro Inc. (TSX-V: CZO) (“Ceapro” or the “Company”), a growth-stage biotechnology company focused on the development and commercialization of active ingredients for healthcare and cosmetic industries, announced today that the German-Canadian Centre for Innovation and Research (“GCCIR”) has made a

Read more

Ceapro Inc. Announces Allowance of Canadian Patent for Enabling Pressurized Gas eXpanded (PGX) Technology

EDMONTON, ALBERTA – September 13, 2016 – Ceapro Inc. (TSX-V: CZO) (“Ceapro” or the “Company”), a growth-stage biotechnology company focused on the development and commercialization of active ingredients for healthcare and cosmetic industries, announced today that the Company has received allowance from the Canadian Patent Office for

Read more

Ceapro Inc. Reports Second Quarter 2016 Financial and Operational Results – Ceapro completes another record-setting quarter for the highest quarterly revenues reported in Company’s history – Clinical program with avenanthramides as anti-inflammatory compound initiated

EDMONTON, ALBERTA – August 24, 2016 – Ceapro Inc.  (TSX-V: CZO) (“Ceapro” or the “Company”), a growth-stage biotechnology company focused on the development and commercialization of active ingredients for healthcare and cosmetic industries, announced today its financial results for the three-month and six-month periods ended June 30,

Read more

Ceapro Inc. Closes Final Tranche of a Brokered Private Placement

EDMONTON, ALBERTA – July 14, 2016 – Ceapro Inc. (TSX-V: CZO) (“Ceapro” or the “Company”), a growth-stage biotechnology company focused on the development and commercialization of active ingredients for healthcare and cosmetic industries, announced today that it has closed the second and final tranche of its previously

Read more

Ceapro Inc. Closes an Initial Tranche of a Brokered Private Placement

EDMONTON, ALBERTA – July 11, 2016 – Ceapro Inc. (TSX-V: CZO) (“Ceapro” or the “Company”), a growth-stage biotechnology company focused on the development and commercialization of active ingredients for healthcare and cosmetic industries, announced today that it has closed the first tranche of its previously announced brokered

Read more

Ceapro Inc. Announces No Material Change

EDMONTON, ALBERTA – July 7, 2016 – Ceapro Inc. (TSX-V: CZO) (“Ceapro” or the “Company”), a growth-stage biotechnology company focused on the development and active ingredients for healthcare and cosmetic industries, is issuing this press release in response to a recent request by the Investment Industry Regulatory

Read more

Ceapro Inc. Announces Brokered Private Placement

EDMONTON, ALBERTA – June 9, 2016 – Ceapro Inc.  (TSX-V: CZO) (“Ceapro” or the “Company”), a growth-stage biotechnology company focused on the development and commercialization of active ingredients for healthcare and cosmetic industries, announced today that it has appointed Echelon Wealth Partners Inc. (“Echelon” or the “Agent”)

Read more

Ceapro Inc. Reports 2016 First Quarter Financial Results and Provides Corporate Update – Ceapro posts highest quarterly revenues reported in Company’s history – Expected commencement of clinical program with avenanthramides as anti-inflammatory compound before year end – Pilot clinical study to develop beta glucan as a cholesterol reducer on track to initiate in Q3 2016

EDMONTON, ALBERTA – May 18, 2016 – Ceapro Inc. (TSX-V: CZO) (“Ceapro” or the “Company”), a growth-stage biotechnology company focused on the development and commercialization of active ingredients for healthcare and cosmetic industries, today announced its financial results for the three-months ended March 31, 2016 and provided

Read more
Page 2 of 1012345...10...Last »